Insmed (Insmed) Days Sales Outstanding

: 41.85 (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Insmed's average Accounts Receivable for the three months ended in Dec. 2023 was $38.4 Mil. Insmed's Revenue for the three months ended in Dec. 2023 was $83.7 Mil. Hence, Insmed's Days Sales Outstanding for the three months ended in Dec. 2023 was 41.85.

The historical rank and industry rank for Insmed's Days Sales Outstanding or its related term are showing as below:

INSM' s Days Sales Outstanding Range Over the Past 10 Years
Min: 33.09 Med: 39.97 Max: 204.67
Current: 40.17

During the past 13 years, Insmed's highest Days Sales Outstanding was 204.67. The lowest was 33.09. And the median was 39.97.

INSM's Days Sales Outstanding is ranked better than
77.9% of 887 companies
in the Biotechnology industry
Industry Median: 72.76 vs INSM: 40.17

Insmed's Days Sales Outstanding declined from Dec. 2022 (43.94) to Dec. 2023 (41.85).

Insmed Days Sales Outstanding Historical Data

The historical data trend for Insmed's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

33.09

39.73

39.62

40.21

42.40

Insmed Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding																43.94	42.14	36.31	38.39	41.85

Competitive Comparison

For the Biotechnology subindustry, Insmed's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insmed Days Sales Outstanding Distribution

For the Biotechnology industry and Healthcare sector, Insmed's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Insmed's Days Sales Outstanding falls into.

Insmed Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Insmed's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (29.713	+	41.189)	/	2 )	/	305.208	*	365
=	35.451					/	305.208	*	365
=	42.40

Insmed's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (35.579	+	41.189)	/	2 )	/	83.693	*	365 / 4
=	38.384					/	83.693	*	365 / 4
=	41.85

Insmed (NAS:INSM) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Insmed Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Insmed's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Insmed (Insmed) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (NAS:INSM) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

INSM:Mexico IM8N:Germany

Address

700 US Highway 202/206, Bridgewater, NJ, USA, 08807

Website

https://www.insmed.com

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Executives

Flammer Martina M.d.	officer: Chief Medical Officer	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Roger Adsett	officer: Chief Commercial Officer	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
John Drayton Wise	officer: Chief Commercial Officer	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Michael Alexander Smith	officer: General Counsel, Senior VP	700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
William Lewis	officer: President & CEO	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Schaeffer Orlov S Nicole	officer: Chief People Strategy Officer	INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Sara Bonstein	officer: Chief Financial Officer	305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Melvin Md Sharoky	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Leo Lee	director	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
David R Brennan	director	C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Steinar J Engelsen	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
John Soriano	officer: Chief Compliance Officer	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Christine A Pellizzari	officer: General Counsel & Secretary	10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Alfred Altomari	director	C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Elizabeth M Anderson	director	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807